These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36570647)

  • 21. A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.
    Liang JA; Sun LM; Lin MC; Chang SN; Sung FC; Muo CH; Kao CH
    Oncologist; 2012; 17(7):986-91. PubMed ID: 22723508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
    Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
    Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
    Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.
    Hammarsten J; Högstedt B
    Eur Urol; 2001 Feb; 39(2):151-8. PubMed ID: 11223674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
    Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer.
    Hammarsten J; Högstedt B
    Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
    Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
    J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physical activity and benign prostatic hyperplasia.
    Platz EA; Kawachi I; Rimm EB; Colditz GA; Stampfer MJ; Willett WC; Giovannucci E
    Arch Intern Med; 1998 Nov; 158(21):2349-56. PubMed ID: 9827786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001-2008.
    Egan KB; Suh M; Rosen RC; Burnett AL; Ni X; Wong DG; McVary KT
    Int J Clin Pract; 2015 Nov; 69(11):1316-25. PubMed ID: 26215544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT; Rademaker A; Lloyd GL; Gann P
    J Urol; 2005 Oct; 174(4 Pt 1):1327-433. PubMed ID: 16145413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Additional Dutasteride on Lower Urinary Tract Symptoms in Patients with Alpha-1 Blocker-Resistant Benign Prostatic Hyperplasia.
    Sengiku A; Miyazaki Y; Sawazaki H; Takahashi T; Ogura K
    Low Urin Tract Symptoms; 2013 Sep; 5(3):159-63. PubMed ID: 26663453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis.
    Li Y; Ma J; Qin XH; Hu CY
    Transl Androl Urol; 2022 Mar; 11(3):313-324. PubMed ID: 35402192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined ethanol extract of Funtumia africana and Abutilon mauritianium leaves improves the lipid profile and kidney function indices of benign prostatic hyperplasia in rats.
    Uroko RI; Chukwu CN; Egba SI; Adamude FA; Ajuzie JC
    Acta Sci Pol Technol Aliment; 2020; 19(4):395-404. PubMed ID: 33179480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia.
    Dimitropoulos K; Gravas S
    Ther Adv Urol; 2016 Feb; 8(1):19-28. PubMed ID: 26834837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimation levels of prostate-specific antigen, interleukin-8, oxidative stress and some inflammatory markers in sera of benign prostatic hyperplasia patients who have smoking habits as a risk factor.
    Al-Barzinj RMGT
    Cell Mol Biol (Noisy-le-grand); 2020 Oct; 66(7):124-130. PubMed ID: 33287932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.